Dotremin

Manufacturer
PureTek Corporation
Effective date
2022-01-14
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
3
Source
full-release
Hydrated at
2026-05-31 20:38:58

Label at a glance#

ProductDotremin
Active ingredientFOLIC ACID, VITAMIN D
Label structure10 sections

Indications and uses

Dotremin™ is indicated for dietary management of patients with unique nutritional needs requiring increased folate levels and Vitamin D supplementation.

Dosage and administration

Take one tablet daily or as directed by a healthcare practitioner. Dotremin™ should be administered under the supervision of a licensed medical practitioner.

Storage and handling

KEEP OUT OF THE REACH OF CHILDREN. Store at 20°-25°C (68°-77°F) [see USP Controlled Room Temperature]. Protect from heat, light, and moisture. Tamper Evident: Do not use if seal is broken or missing

Label contents#

Full prescribing information#

DESCRIPTION

DESCRIPTION SECTION

Dotremin™ is an orally administered prescription folate product for the dietary management of patients with unique nutritional needs requiring increased folate levels and Vitamin D supplementation due to Vitamin D deficiency.


Dotremin™ should be administered under the supervision of a licensed medical practitioner.


Each tablet contains:

Folate (as folic acid)……………………..1700 mcg DFE † (1000 mcg folic acid)

Vitamin D 3 (cholecalciferol)………....250 mcg (10,000 IU)

Each tablet contains the following inactive ingredients:

lactose monohydrate, magnesium stearate, microcrystalline cellulose, sodium carboxymethyl starch, stearic acid, DL-alpha- tocopheryl acetate.

† Dietary Folate Equivalent

INDICATIONS AND USAGE

INDICATIONS & USAGE SECTION

Dotremin™ is indicated for dietary management of patients with unique nutritional needs requiring increased folate levels and Vitamin D supplementation.

CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

The in vivo synthesis of the major biologically active metabolites of Vitamin D occurs in two steps. The first hydroxylation of ergocalciferol takes place in the liver (to 25-hydroxyvitamin D) and the second in the kidneys (to 1,25-dihydroxyvitamin D). Vitamin D metabolites promote the active absorption of calcium and phosphorus by the small intestine, thus elevating serum calcium and
phosphate levels sufficiently to permit bone mineralization. Vitamin D metabolites also mobilize calcium and phosphate from bone and probably increase the reabsorption of calcium and perhaps also of phosphate by the renal tubules.

There is a time lag of 10 to 24 hours between the administration of vitamin D and the initiation of its action in the body due to the necessity of synthesis of the active metabolites in the liver and kidneys. Parathyroid hormone is responsible for the regulation of this metabolism in the kidneys.

CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

This product is contraindicated in patients with a known hypersensitivity to any of the ingredients. Dotremin ™ is contraindicated in patients with hypercalcemia, malabsorption syndrome, abnormal sensitivity to the toxic effects of vitamin D, and hypervitaminosis D.

WARNINGS AND PRECAUTIONS

WARNINGS AND PRECAUTIONS SECTION

KEEP OUT OF THE REACH OF CHILDREN.

Tell your doctor if you have: kidney problems, thyroid disease. This medication should be used as directed during pregnancy or while breastfeeding. Consult your doctor.

Folic acid alone is improper therapy in the treatment of pernicious anemia and other megaloblastic anemias where vitamin B12 is deficient. Folic acid in doses above 0.1 mg daily may obscure pernicious anemia in that hematologic remission can occur while neurological manifestations progress.

ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

Allergic sensitization has been reported following both oral and parenteral administration of folic acid.

You should call your doctor for medical advice about serious adverse events. To report adverse side effects or to obtain product information, contact PureTek Corporation, at 1-877-921-7873.

DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

Take one tablet daily or as directed by a healthcare practitioner.

Dotremin™ should be administered under the supervision of a licensed medical practitioner.

HOW SUPPLIED

HOW SUPPLIED SECTION

Dotremin™ Tablets are supplied as round, light yellow tablets with one side scored, the other side plain and dispensed in child-resistant bottles of 30 tablets (NDC 59088-524-54*).

* This product is a prescription-folate with or without other dietary ingredients that – due to increased folate levels (AUG 2, 1973 FR 20750), requires an Rx on the label because of increased risk associated with masking of B 12 deficiency (pernicious anemia). Based on our assessment of the risk of obscuring pernicious anemia, this product requires licensed medical supervision, an Rx status, and a National Drug Code (NDC) or similarly-formatted product code, as required by pedigree reporting requirements and supply-chain control as well as in some cases, for insurance-reimbursement applications.

All prescriptions using this product shall be pursuant to state statutes as applicable. This is not an Orange Book product. This product may be administered only under a physician’s supervision. There are no implied or explicit claims on therapeutic equivalence

STORAGE

STORAGE AND HANDLING SECTION

KEEP OUT OF THE REACH OF CHILDREN.

Store at 20°-25°C (68°-77°F) [see USP Controlled Room Temperature].

Protect from heat, light, and moisture.

Tamper Evident: Do not use if seal is broken or missing

Dotremin™

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

Manufactured in the USA by:
PureTek Corporation
Panorama City, CA 91402
For questions or information
call toll-free: 877-921-7873

labellabel

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYSPL version
2569082vitamin D3 250 MCG (10,000 UNT) / folate 1700 MCG DFE (1000 mcg folic acid) Oral TabletPSN3
2569082cholecalciferol 0.25 MG / folic acid 1 MG Oral TabletSCD3
2569082cholecalciferol 0.25 MG / folate 1 MG Oral TabletSY3
2569082vitamin D3 250 MCG (10,000 UNT) / folate 1700 MCG DFE (1000 mcg folic acid) Oral TabletSY3

DailyMed Pharmacologic Classes#

Class, Version, Type table
ClassVersionTypeEffective
CHOLECALCIFEROL Pharmacologic Class Indexing2Indexing - Pharmacologic Class20180813

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
91c62db0-0295-c81c-d10a-0856c259edd6Product name220200428
d32bc2b8-0bb7-2216-87aa-24639646e202Product name320190619
60c52429-fcef-eb54-2387-43bc9e4f296bProduct name120140508

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
59088-524-54Dotremin30 in 1 BOTTLE, PLASTICTABLET303

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDCDashboard titleSPL versionValidationDashboard ZIP
59088-524DOTREMIN (FOLIC ACID, VITAMIN D3) TABLET [PURETEK CORPORATION]3Current NDC, Legacy NDC, 1 package rows20220115_cd132db2-7ff7-a9eb-e053-2995a90a02c5.zip

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
59088-524-54EA - Each59088-52463e156a4-4ddc-40fa-8a52-d980d4d24ef912022-02-07

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 11 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
59088-52459088-524-54

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 8 matching rows.

Source Document#

Source XML

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
DotreminFOLIC ACID, VITAMIN D3PureTek Corporationcd132db2-7ff7-a9eb-e053-2995a90a02c52022-01-14Warnings, Adverse reactionsExact identifier
ndc (package): 59088-524-54
ndc (product): 59088-524
ndc11 (package): 59088052454
spl id: d5922f8a-7f55-7e96-e053-2a95a90a70a1
spl set id: cd132db2-7ff7-a9eb-e053-2995a90a02c5

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.